Saturday 17 October 2026
Export ALUR’s income statement to Excel — free account
Allurion Technologies, Inc.
ALUR Healthcare Medical Devices
Allurion Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.2 million, down 52.6% from fiscal 2024. In the quarter to March 2026, revenue fell 47.2%, EPS fell 46.5% and free cash flow grew 66.0%, each against the same quarter a year earlier.
0.48
0.12
−20.00%
Follow ALUR
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 237.50 | 241.75 | 65.75 | 6.50 | 1.02 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 267.50 | 252.50 | 273.50 | 98.75 | 16.81 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 252 | 137 | 41 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.21 | 0.23 | 0.37 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 64 | 53 | 32 | 15 | ||||
| Gross margin, % | — | — | — | — | — | — | 79.00 | 77.61 | 66.97 | 62.84 | |||||
| EBT | — | — | — | — | 0 | 6 | (38) | (83) | (6) | (29) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | (58.56) | (154.40) | (20.18) | (188.32) | |||||
| Net income | — | 0 | — | — | 0 | 6 | (38) | (83) | (7) | (29) | |||||
| Depreciation | — | — | — | — | — | — | 1 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 894.30 | 563.40 | 214.21 | 30.26 | ||||
| Earnings | — | — | — | — | (0.10) | 101.59 | (525.56) | (865.82) | (48.03) | (48.92) | |||||
| Cash flow | — | — | — | — | 0.00 | (36.62) | (654.33) | (674.20) | (282.19) | (57.51) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | (21.59) | (16.92) | (4.08) | 0.00 | |||||
| Free cash flow | — | — | — | — | 0.00 | (36.62) | (675.92) | (691.13) | (286.26) | (57.51) | |||||
| Book value | — | — | — | — | 0.40 | (1,084.94) | (450.06) | (751.29) | (520.20) | (153.37) | |||||
| Shares, m | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | 0.00 | 0.16 | 0.05 | 0.04 | |||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 0.54 | 1.90 | 4.36 | |||||
| EV/FCF | — | — | — | — | — | — | (1.38) | (0.44) | (1.42) | (2.25) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (2) | (47) | (64) | (42) | (29) | ||||
| Capex | — | — | — | — | — | — | (2) | (2) | (1) | — | |||||
| Free cash flow | — | — | — | — | 0 | (2) | (49) | (66) | (43) | (29) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | 1 | (32) | (1) | 8 | (26) | ||||
| Total debt | — | — | — | — | 0 | 1 | 56 | 39 | 36 | — | |||||
| Net debt | — | — | — | — | 0 | 1 | 49 | 1 | 20 | (5) | |||||
| Shareholders’ equity | — | — | — | — | 0 | (62) | (32) | (71) | (78) | (77) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (3.15) | 1.33 | (8.88) | (137.33) | (13.77) | (118.37) | ||||
| ROIC | — | — | — | — | (2.28) | 0.00 | (121.52) | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | 0.00 | (18.74) | 86.65 | 163.14 | 9.64 | 37.06 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Mar 2026
Charts ten years each
Allurion Technologies, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ARAY Accuray Incorporated | $20.8M | — (loss-making) | — (loss-making) | −20.87% (below 0%: shrinking) | n/m | +117.83% (above 0%: growing) | 35.22% | 5.47% | Compare |
| MODD Modular Medical, Inc. | $20.5M | — (loss-making) | — | — | n/m | −5.61% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PAVM PAVmed Inc. | $19.4M | — (loss-making) | — (loss-making) | +450.00% (above 0%: growing) | n/m | −125.63% (below 0%: shrinking) | (269.70%) | (21,278.79%) | Compare |
| BDMD Baird Medical Investment Holdings Limited | $19.2M | — (loss-making) | — | — | n/m | −598.12% (below 0%: shrinking) | — | — | Compare |
| LFWD Lifeward Ltd. | $17.2M | — (loss-making) | — (loss-making) | +15.71% (above 0%: growing) | n/m | −52.77% (below 0%: shrinking) | 40.90% | (62.69%) | Compare |
| ALUR Allurion Technologies, Inc. | $16.7M | — (loss-making) | — (loss-making) | −47.19% (below 0%: shrinking) | n/m | +65.98% (above 0%: growing) | 41.70% | (126.60%) | |
| HSCS HeartSciences Inc. | $15.4M | — (loss-making) | — (loss-making) | −46.15% (below 0%: shrinking) | n/m | +18.18% (above 0%: growing) | 61.90% | (139,957.14%) | Compare |
| IRIX IRIDEX Corporation | $14.5M | — (loss-making) | — (loss-making) | −7.41% (below 0%: shrinking) | n/m | +130.24% (above 0%: growing) | 34.19% | (8.19%) | Compare |
| RBOT Vicarious Surgical Inc. | $14.3M | — (loss-making) | — | — | n/m | +47.33% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $18.2M | — | — | −7.41% | — | +6.28% | 34.19% | (8.19%) |
Allurion Technologies, Inc. (ALUR) key facts
- Concern: Allurion Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.2 million, down 52.6% from fiscal 2024.
- Allurion Technologies, Inc. (ALUR) is a Medical Devices company in the Healthcare sector.
- As of October 15, 2026, ALUR traded at $0.48, a market capitalization of $16.7 million.
- Return on equity was 37.1% and debt-to-equity 0.00.
- Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −29.57 (distress zone) for fiscal 2025.